We Accelerate Change...
TREAT-NMD is a global network of experts in the neuromuscular field. Everyone in our network helps us work towards our mission to accelerate the development of effective treatments; and establish the best in diagnosis and care for people worldwide.
20 Years of TREAT-NMD - The Past and Future of Translational Research in Neuromuscular Diseases
As we mark our 20th anniversary, join us in our founding city of Newcastle for an opportunity to reflect on two decades of progress and look ahead to the future we want to shape together. Register your interest.
Who We Support...
What We Do...
Advisory Committee for Therapeutics
Evaluating the therapeutic potential of drugs to optimise their design and development.
Global Registry Network
A federated network of over 70 individual, independent, national (or regional) patient and clinician reported registries that collect data on neuromuscular patients from more than 40 countries worldwide.
Education
Giving healthcare providers greater understanding of the diagnosis and management of neuromuscular diseases.
Post-Marketing Surveillance
TREAT-NMD contributes to post-marketing surveillance in the neuromuscular field by acting as an independent partner of Life Sciences Industry and Clinical Research Organisations to facilitate and contribute to international, disease specific PMS systems and processes to fulfil regulatory requirements.
Resources and Support
Providing information to patients and health care providers to improve patients’ diagnosis and care.
Connecting the Network
Bringing people together to accelerate cutting-edge therapies for otherwise unmet needs.
TREAT-NMD Latest News...
New publication reflects on 15 years of TACT and its impact on neuromuscular drug development
We’re pleased to share a new publications in the Journal of Neuromuscular Diseases exploring 15 years of experience from the TREAT-NMD Advisory Committee for Therapeutics (TACT), highlighting how expert multidisciplinary […]
NEW DATE ANNOUNCMENT: Expert Masterclass on Myotonic Dystrophy Type 1 | 19th November 2026
New Date: 19 November 2026 Format: Virtual Event TREAT‑NMD has announced a new date for its Myotonic Dystrophy Type 1 Expert Masterclass, which will now take place virtually on 19 […]
We’re Recruiting: Volunteer Committee Member (Neuromuscular Disease Experience)
Join the TREAT‑NMD Information & Technology Advisory Committee (ITAC) TREAT‑NMD’s ITAC is seeking a passionate volunteer IT member with experience or strong familiarity with neuromuscular diseases to help guide the strategic […]
TACT Call for Applicants
Applications are now open for the next TACT review meeting, which will take place in Croatia from 24 to 26 April 2026. TACT continues to support the neuromuscular community by […]
See You in Lisbon Next Week for the TREAT‑NMD Conference
We are looking forward to welcoming you to Lisbon next week for the TREAT‑NMD Conference, which will take place from 10 to 12 February. This year’s theme, Addressing Challenges in […]
Upcoming TREAT‑NMD Masterclasses: Advancing Knowledge, Strengthening Care
TREAT‑NMD is delighted to announce a series of upcoming educational masterclasses designed to support healthcare professionals in delivering the highest standards of neuromuscular care. With expert faculty, clinical best practice, […]
Support Needed: Translating the LGMD Family Guide
TREAT-NMD and Sarepta Therapeutics launched the first plain-language LGMD Family Guide last year to support people living with limb girdle muscular dystrophy (LGMD), their families, and non-specialist clinicians. The guide […]
FDA Approves New SMA Treatment: A Major Milestone for the Community
We are thrilled to share an important development for the spinal muscular atrophy (SMA) community. The U.S. Food and Drug Administration (FDA) has approved Novartis’ Itvisma® offering a new treatment […]
Help Us Shape What it Means to be a Member of TREAT-NMD
We’re currently working on updating the benefits we offer to our TREAT-NMD members and we want your input! As part of this development, we’ve created a short feedback form to […]
